CN103664786A - 一类水杨醛的二氢吡唑磺胺衍生物的合成及在抗癌药物中的应用 - Google Patents
一类水杨醛的二氢吡唑磺胺衍生物的合成及在抗癌药物中的应用 Download PDFInfo
- Publication number
- CN103664786A CN103664786A CN201310541156.6A CN201310541156A CN103664786A CN 103664786 A CN103664786 A CN 103664786A CN 201310541156 A CN201310541156 A CN 201310541156A CN 103664786 A CN103664786 A CN 103664786A
- Authority
- CN
- China
- Prior art keywords
- preparation
- pyrazoline
- dihydro
- sulfonamide derivatives
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 55
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 4
- 229940041181 antineoplastic drug Drugs 0.000 title claims abstract description 4
- 229940124530 sulfonamide Drugs 0.000 title abstract description 8
- KEQTWHPMSVAFDA-UHFFFAOYSA-N 2,3-dihydro-1h-pyrazole Chemical compound C1NNC=C1 KEQTWHPMSVAFDA-UHFFFAOYSA-N 0.000 title abstract 6
- 238000001308 synthesis method Methods 0.000 title abstract 3
- -1 pyrazoline sulphone amide Chemical class 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 15
- SMQUZDBALVYZAC-UHFFFAOYSA-N salicylaldehyde Chemical compound OC1=CC=CC=C1C=O SMQUZDBALVYZAC-UHFFFAOYSA-N 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 6
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 238000013019 agitation Methods 0.000 claims description 3
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 claims description 3
- 238000001953 recrystallisation Methods 0.000 claims description 3
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 239000012670 alkaline solution Substances 0.000 claims description 2
- 238000004440 column chromatography Methods 0.000 claims description 2
- 239000012043 crude product Substances 0.000 claims description 2
- 239000000047 product Substances 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 230000004071 biological effect Effects 0.000 abstract description 5
- 206010006187 Breast cancer Diseases 0.000 abstract description 4
- 208000026310 Breast neoplasm Diseases 0.000 abstract description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract description 4
- 230000001093 anti-cancer Effects 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 239000013078 crystal Substances 0.000 description 23
- 239000000243 solution Substances 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 235000015097 nutrients Nutrition 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 201000005296 lung carcinoma Diseases 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 150000003217 pyrazoles Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 2
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical group C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- OMBVEVHRIQULKW-DNQXCXABSA-M (3r,5r)-7-[3-(4-fluorophenyl)-8-oxo-7-phenyl-1-propan-2-yl-5,6-dihydro-4h-pyrrolo[2,3-c]azepin-2-yl]-3,5-dihydroxyheptanoate Chemical compound O=C1C=2N(C(C)C)C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C=3C=CC(F)=CC=3)C=2CCCN1C1=CC=CC=C1 OMBVEVHRIQULKW-DNQXCXABSA-M 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 1
- BGAJNPLDJJBRHK-UHFFFAOYSA-N 3-[2-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NN=C(N2C(=C3CN(CCC(O)=O)CCC3=N2)C)S1 BGAJNPLDJJBRHK-UHFFFAOYSA-N 0.000 description 1
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N Aminoantipyrine Natural products CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 1
- ISMDILRWKSYCOD-GNKBHMEESA-N C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O Chemical compound C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O ISMDILRWKSYCOD-GNKBHMEESA-N 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- XOVVXNLQVMSIMX-UHFFFAOYSA-N NS(c(cc1)ccc1N(C(C1)c2cc(Cl)ccc2O)N=C1c(cc1)ccc1Br)(=O)=O Chemical compound NS(c(cc1)ccc1N(C(C1)c2cc(Cl)ccc2O)N=C1c(cc1)ccc1Br)(=O)=O XOVVXNLQVMSIMX-UHFFFAOYSA-N 0.000 description 1
- WOBWVPAYWXXCTM-UHFFFAOYSA-N NS(c(cc1)ccc1N(C(C1)c2cc(Cl)ccc2O)N=C1c(cccc1)c1Cl)(=O)=O Chemical compound NS(c(cc1)ccc1N(C(C1)c2cc(Cl)ccc2O)N=C1c(cccc1)c1Cl)(=O)=O WOBWVPAYWXXCTM-UHFFFAOYSA-N 0.000 description 1
- BAEAVVXMBRPJGE-UHFFFAOYSA-N NS(c(cc1)ccc1N(C(C1)c2ccccc2O)N=C1c(cc1)cc(Cl)c1Cl)(=O)=O Chemical compound NS(c(cc1)ccc1N(C(C1)c2ccccc2O)N=C1c(cc1)cc(Cl)c1Cl)(=O)=O BAEAVVXMBRPJGE-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 229940089256 fungistat Drugs 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960005222 phenazone Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003219 pyrazolines Chemical class 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一类水杨醛的二氢吡唑磺胺衍生物的合成及制备,其特征是它有如下通式:
Description
技术领域
本发明的目的在于提供一类水杨醛的二氢吡唑磺胺衍生物的合成及在抗癌药物中的应用
背景技术
磺胺类药物具有多种生物活性,一直是药物化学领域研究的热点,在抗菌、降血压、利尿等方面有广泛应用。但是由于该类药物是抑菌剂而无杀菌作用,易产生耐药性以及经常使用会产生许多不良反应,从而使其应用范围受到了极大的限制。尤其是因其易产生抗药性,使用范围已逐渐减小。但是近年来的文献多次报道了其衍生物的具有除抗菌外其他方面的活性,其中最显著的是抗肿瘤活性.
吡唑是一类重要的杂环化合物,广泛分布在自然界中。自从含吡唑环的安替吡啉被发现具有镇痛消炎及退热作用以来,该类化合物因其具有高效、低毒,以及其环上取代基的多方位变换的性质而在药物领域中得到广泛应用。研究发现吡唑类化合物具有消炎、止痛、抑菌、杀菌、抗高血糖、抗癌、抗凝血剂等药理活性。近年来,许多新型吡唑类医药相继商品化,对吡唑类化合物的深入研究已成为当今药物设计合成研究的热点之一。
2H吡唑是极为重要的含氮的五元杂环化合物,它具有较强的生物活性,比如抗肿瘤、抗菌、抗病毒、抗真菌、抗结核、杀虫等活性。它是一个具有各种药理特性的结构性存在亚基,是存在普遍药用生物活性的活性化合物先导。更为重要的是:因为2H吡唑多是手性的,导致环上的取代及分子的构象具有更大的多变性,具有更好的生物活性潜质!2H吡唑类化合物在有机合成和其他领域中的应用越来越广泛,且手性2H吡唑类化合物具有诸多生物及药理性能,促进了药物的巨大发展,为以后的药物开发研究提供了很大的研究空间,发展前景非常广阔。因此构建具有2H吡唑结构的杂环体系具有重要的意义,是近几年被关注的热点。
基于此,本发明将不同磺胺以及具有很好生物活性的取代水杨醛引入到二氢吡唑衍生物中,设计合成了一系列结构新颖水杨醛的二氢吡唑磺胺衍生物,期望具有更好的生物活性、更高的选择性、更低的毒性、更长或更短的残效期等.
发明内容
本发明的技术方案如下:
1.一类水杨醛的二氢吡唑磺胺衍生物的合成及制备,其特征是它有如下通式:
一种上述水杨醛的二氢吡唑磺胺衍生物的合成,它由下列步骤组成:
步骤1.在搅拌下,依次向反应容器中加入适量的水杨醛1-3同取代基的苯乙酮、碱溶液、有机溶剂,适当的温度下继续搅拌反应适当的时间后,过滤,洗涤,干燥得中间体4-26。
步骤2.在反应容器中加入适量的查尔酮的衍生物4-26、酸、对肼基苯磺酰胺、适量的有机溶剂,在适当的温度下搅拌反应一段时间(TLC跟踪反应,直至至少一种原料很少甚至没有),过滤得粗产品,粗品经柱层析或采用适当的有机溶剂重结晶提纯得目标化合物27-49。
本发明水杨醛的二氢吡唑磺胺衍生物对人乳腺癌细胞(MCF-7)及肺癌细胞(A549)有明显的抑制作用,因此本发明的二氢吡唑磺胺衍生物可以应用于制备抗肿瘤药物。
具体实施方式
实施例一:4-(5-(2-羟苯基)-3-苯基-4,5-二氢吡唑)苯磺酰胺(化合物27)的制备
在搅拌下依次将查尔酮(1.0g,4.46mmol)、乙醇(25mL)、对肼基苯磺酰胺(0.97g,5.03mmol)、乙酸(1.0mL)加入到50mL的圆底烧瓶中,仍有部分固体不溶;将烧瓶转移到油浴锅中,回流反应6h,TLC跟踪反应(展开剂VAcOEt:V正己 烷=1:2),反应结束后,过滤,固体用蒸馏水洗涤,最后真空干燥,将得到的固体溶于无水乙醇重结晶提纯得到晶体状目标化合物。
黄色晶体,产率41.15%.m.p.266~268℃;1H NMR(DMSO-d6,400MHz)δ:9.95(s,1H,OH),7.79~6.68(m,15H,ArH and NH2),5.72(dd,J1=5.1,J2=5.1Hz,1H,5-H),3.95(dd,J1=12.2,J2=12.1Hz,1H,4-Hb),3.13(dd,J1=5.2,J2=5.1Hz,1H,4-Ha).
实施例二:4-(3-(2-氯苯基)-5-(2-羟苯基)-4,5-二氢吡唑)苯磺酰胺(化合物28)的制备
制备方法同实施例一。
黄色晶体,产率63.5%.m.p.220~222℃;1H NMR(DMSO-d6,400MHz)δ:9.93(s,1H,OH),7.80~6.71(m,14H,ArH and NH2),5.73(dd,J1=5.1,J2=5.1Hz,1H,5-H),4.09(dd,J1=12.2,J2=12.1Hz,1H,4-Hb),3.22(dd,J1=5.2,J2=5.1Hz,1H,4-Ha).
实施例三:4-(3-(4-乙氧苯基)-5-(2-羟苯基)-4,5-二氢吡唑)苯磺酰胺(化合物29)的制备
制备方法同实施例一。
白色晶体,产率39.5%.m.p.243~245℃;1H NMR(DMSO-d6,400MHz)δ:9.94(s,1H,OH),7.72~6.68(m,14H,ArH and NH2),5.67(dd,J1=4.9,J2=6.1Hz,1H,5-H),4.06(m,2H,OCH2),3.92(dd,J1=12.1,J2=12.0Hz,1H,4-Hb),3.08(dd,J1=6.9,J2=5.0Hz,1H,4-Ha),1.34(t,J=6.9Hz,3H,CH3).
实施例四:4-(3-(4-溴苯基)-5-(2-羟苯基)-4,5-二氢吡唑)苯磺酰胺(化合物30)的制备
制备方法同实施例一。
黄色晶体,产率58.0%.m.p.241~243℃;1H NMR(DMSO-d6,400MHz)δ:9.96(s,1H,OH),7.73~6.68(m,14H,ArH and NH2),5.72(dd,J1=5.2,J2=5.2Hz,1H,5-H),3.93(dd,J1=12.4,J2=12.1Hz,1H,4-Hb),3.11(dd,J1=5.2,J2=5.1Hz,1H,4-Ha).
实施例五:4-(5-(2-羟苯基)-3-(3-甲氧苯基)-4,5-二氢吡唑)苯磺酰胺(化合物31)的制备
制备方法同实施例一。
黄色晶体,产率60.1%.m.p.231~233℃;1H NMR(DMSO-d6,400MHz)δ:9.95(s,1H,OH),7.60~6.68(m,14H,ArH and NH2),5.72(dd,J1=5.1,J2=5.2Hz,1H,5-H),3.94(dd,J1=12.2,J2=12.2Hz,1H,4-Hb),3.82(s,3H,OCH3),3.13(dd,J1=5.2,J2=5.1Hz,1H,4-Ha).
实施例六:4-(3-(3,4二甲苯基)-5-(2-羟苯基)-4,5-二氢吡唑)苯磺酰胺(化合物32)的制备
制备方法同实施例一。
黄色晶体,产率31.0%.m.p.245~247℃;1H NMR(DMSO-d6,400MHz)δ:9.93(s,1H,OH),7.58~6.66(m,13H,ArH and NH2),5.68(dd,J1=4.8,J2=5.0Hz,1H,5-H),3.91(dd,J1=12.2,J2=12.0Hz,1H,4-Hb),3.08(dd,J1=4.9,J2=4.8Hz,1H,4-Ha),2.26(d,6H,CH3).
实施例七:4-(3-(3,4-二氯苯基)-5-(2-羟苯基)-4,5-二氢吡唑)苯磺酰胺(化合物33)的制备
制备方法同实施例一。
黄色晶体,产率63.4%.m.p.210~212℃;1H NMR(DMSO-d6,400MHz)δ:9.96(s,1H,OH),8.00~6.69(m,13H,ArH and NH2),5.77(dd,J1=5.4,J2=5.6Hz,1H,5-H),3.94(dd,J1=12.5,J2=12.4Hz,1H,4-Hb),3.18(dd,J1=5.5,J2=5.3Hz,1H,4-Ha)
实施例八:4-(5-(5-氯-2羟苯基)-3-(4-氟苯基)-4,5-二氢吡唑)苯磺酰胺(化合物34)的制备
制备方法同实施例一。
黄色晶体,产率77.6%.m.p.187~188℃;1H NMR(DMSO-d6,400MHz)δ:10.25(s,1H,OH),7.85~6.78(m,13H,ArH and NH2),5.73(dd,J1=5.1,J2=5.2Hz,1H,5-H),3.96(dd,J1=12.2,J2=12.1Hz,1H,4-Hb),3.19(dd,J1=5.2,J2=4.9Hz,1H,4-Ha).
实施例九:4-(5-(5-氯-2羟苯基)-3-(2-氯苯基)-4,5-二氢吡唑)苯磺酰胺(化合物35)的制备
制备方法同实施例一。
白色晶体,产率22.3%.m.p.197~198℃;1H NMR(DMSO-d6,400MHz)δ:10.33(s,1H,OH),7.64~6.78(m,13H,ArH and NH2),5.68(dd,J1=5.2,J2=5.3Hz,1H,5-H),3.95(dd,J1=12.3,J2=12.5Hz,1H,4-Hb),3.18(dd,J1=4.3,J2=4.3Hz,1H,4-Ha).
实施例十:4-(5-(5-氯-2羟苯基)-3-苯基)-4,5-二氢吡唑)苯磺酰胺(化合物36)的制备
制备方法同实施例一。
黄色晶体,产率71.3%.m.p.248~250℃;1H NMR(DMSO-d6,300MHz)δ:10.28(s,1H,OH),7.81~6.68(m,14H,ArH and NH2),5.72(dd,J1=5.4,J2=5.5Hz,1H,5-H),3.95(dd,J1=12.3,J2=12.3Hz,1H,4-Hb),3.13(dd,J1=5.4,J2=5.4Hz,1H,4-Ha).
实施例十一:4-(5-(5-氯-2羟苯基)-3-(4-氯苯基)-4,5-二氢吡唑)苯磺酰胺(化合物37)的制备
制备方法同实施例一。
黄色晶体,产率18.3%.m.p.193~196℃;1H NMR(DMSO-d6,400MHz)δ:10.3(s,1H,OH),7.81~6.8(m,13H,ArH and NH2),5.69(dd,J1=5.4,J2=5.5Hz,1H,5-H),3.95(dd,J1=12.3,J2=12.3Hz,1H,4-Hb),3.17(dd,J1=5.5,J2=5.4Hz,1H,4-Ha).
实施例十二:4-(5-(5-氯-2羟苯基)-3-(4-甲氧苯基)-4,5-二氢吡唑)苯磺酰胺(化合物38)的制备
制备方法同实施例一。
黄色晶体,产率78.3%.m.p.192~195℃;1H NMR(DMSO-d6,400MHz)δ:10.29(s,1H,OH),7.75~6.76(m,13H,ArH and NH2),5.64(dd,J1=5.3,J2=5.4Hz,1H,5-H),3.93(dd,J1=12.1,J2=12.0Hz,1H,4-Hb),3.81(s,3H,OCH3),3.12(dd,J1=5.3,J2=5.2Hz,1H,4-Ha).
实施例十三:4-(3-(4-溴苯基)-5-(5-氯-2-羟苯基)-4,5-二氢吡唑)苯磺酰胺(化合物39)的制备
制备方法同实施例一。
黄色晶体,产率40.6%.m.p.195~197℃;1H NMR(DMSO-d6,300MHz)δ:10.3(s,1H,OH),7.74~6.77(m,13H,ArH and NH2),5.63(dd,J1=5.04,J25.2Hz,1H,5-H),3.93(dd,J1=12.1,J2=12.0Hz,1H,4-Hb),3.12(dd,J1=5.1,J2=5.0Hz,1H,4-Ha).
实施例十四:4-(5-(5-氯-2羟苯基)-3-(3,4-二氯苯基)-4,5-二氢吡唑)苯磺酰胺(化合物40)的制备
制备方法同实施例一。
白色晶体,产率34.8%.m.p.189~191℃;1H NMR(DMSO-d6,400MHz)δ:10.21(s,1H,OH),7.96~6.81(m,12H,ArH and NH2),5.8(dd,J1=5.3,J2=5.5Hz,1H,5-H),3.97(dd,J1=12.5,J2=12.3Hz,1H,4-Hb),3.3(dd,J1=5.5,J2=5.4Hz,1H,4-Ha).
实施例十五:4-(5-(5-氯-2羟苯基)-3-(4-乙氧苯基)-4,5-二氢吡唑)苯磺酰胺(化合物41)的制备
制备方法同实施例一。
黄色晶体,产率40.2%.m.p.183~186℃;1H NMR(DMSO-d6,400MHz)δ:10.3(s,1H,OH),7.73~6.76(m,13H,ArH and NH2),5.63(dd,J1=5.0,J2=5.2Hz,1H,5-H),4.08(m,2H,OCH2),3.92(dd,J1=12.2,J2=12.0Hz,1H,4-Hb),3.12(dd,J1=5.2,J2=5.2Hz,1H,4-Ha),1.35(m,3H,CH3).
实施例十六:4-(5-(5-氯-2羟苯基)-3-(3-甲氧苯基)-4,5-二氢吡唑)苯磺酰胺(化合物42)的制备
制备方法同实施例一。
黄色晶体,产率45.6%.m.p.191~192℃;1H NMR(DMSO-d6,400MHz)δ:10.32(s,1H,OH),7.62~6.76(m,13H,ArH and NH2),5.67(dd,J1=5.1,J2=5.1Hz,1H,5-H),3.94(dd,J1=12.1,J2=12.4Hz,1H,4-Hb),3.85(s,3H,OCH3),3.16(dd,J1=5.2,J2=5.2Hz,1H,4-Ha).
实施例十七:4-(5-(5-溴-2羟苯基)-3-苯基-4,5-二氢吡唑)苯磺酰胺(化合物43)的制备
制备方法同实施例一。
白色晶体,产率33.5%.m.p.248~250℃;1H NMR(DMSO-d6,400MHz)δ:10.34(s,1H,OH),7.81~6.90(m,14H,ArH and NH2),5.68(dd,J1=5.3,J2=5.4Hz,1H,5-H),3.97(dd,J1=12.2,J2=12.2Hz,1H,4-Hb),3.17(dd,J1=5.4,J2=5.3Hz,1H,4-Ha).
实施例十八:4-(5-(5-溴-2羟苯基)-3-(3-甲氧苯基)-4,5-二氢吡唑)苯磺酰胺(化合物44)的制备
制备方法同实施例一。
黄色晶体,产率29.7%.m.p.184~185℃;1H NMR(DMSO-d6,400MHz)δ:10.33(s,1H,OH),7.64~6.90(m,13H,ArH and NH2),5.68(dd,J1=5.2,J2=5.3Hz,1H,5-H),3.96(dd,J1=12.3,J2=12.2Hz,1H,4-Hb),3.83(s,3H,OCH3),3.17(dd,J1=5.4,J2=5.3Hz,1H,4-Ha),
实施例十九:4-(5-(5-溴-2羟苯基)-3-(4-氟苯基)-4,5-二氢吡唑)苯磺酰胺(化合物45)的制备
制备方法同实施例一。
白色晶体,产率70.8%.m.p.195~196℃;1H NMR(DMSO-d6,400MHz)δ:10.34(s,1H,OH),7.86~6.90(m,13H,ArH and NH2),5.68(dd,J1=5.3,J2=5.5Hz,1H,5-H),3.97(dd,J1=12.3,J2=12.2Hz,1H,4-Hb),3.18(dd,J1=5.4,J2=5.3Hz,1H,4-Ha).
实施例二十:4-(5-(5-溴-2羟苯基)-3-(2-氯苯基)-4,5-二氢吡唑)苯磺酰胺(化合物46)的制备
制备方法同实施例一。
黄色晶体,产率68.7%.m.p.182~183℃;1H NMR(DMSO-d6,400MHz)δ:10.32(s,1H,OH),7.80~6.88(m,13H,ArH and NH2),5.70(dd,J1=5.2,J2=5.3Hz,1H,5-H),4.10(dd,J1=12.2,J2=12.2Hz,1H,4-Hb),3.26(dd,J1=5.4,J2=5.2Hz,1H,4-Ha).
实施例二十一:4-(5-(5-溴-2羟苯基)-3-(4-氯苯基)-4,5-二氢吡唑)苯磺酰胺(化合物47)的制备
制备方法同实施例一。
黄色晶体,产率67.1%.m.p.179~180℃;1H NMR(DMSO-d6,400MHz)δ:10.32(s,1H,OH),7.80~6.88(m,13H,ArH and NH2),5.70(dd,J1=5.4,J2=5.5Hz,1H,5-H),4.10(dd,J1=12.4,J2=12.3Hz,1H,4-Hb),3.26(dd,J1=5.6,J2=5.4Hz,1H,4-Ha).
实施例二十二:4-(5-(5-溴-2羟苯基)-3-(4-溴苯基)-4,5-二氢吡唑)苯磺酰胺(化合物48)的制备
制备方法同实施例一。
黄色晶体,产率63.4%.m.p.185~186℃;1H NMR(DMSO-d6,400MHz)δ:10.33(s,1H,OH),7.73~6.90(m,13H,ArH and NH2),5.68(dd,J1=5.4,J2=5.5Hz,1H,5-H),3.94(dd,J1=12.4,J2=12.2Hz,1H,4-Hb),3.16(dd,J1=5.5,J2=5.4Hz,1H,4-Ha).
实施例二十三:4-(5-(5-溴-2-羟苯基)-3-(3,4-二氯苯基)4,5-二氢吡唑)苯磺酰胺(化合物49)的制备
制备方法同实施例一。
黄色晶体,产率63.4%.m.p.180~181℃;1H NMR(DMSO-d6,400MHz)δ:10.35(s,1H,OH),8.00~6.69(m,12H,ArH and NH2),5.72(dd,J1=5.4,J2=5.6Hz,1H,5-H),3.94(dd,J1=12.5,J2=12.4Hz,1H,4-Hb),3.29(dd,J1=5.5,J2=5.3Hz,1H,4-Ha).
实施例二十四:磺胺类衍生物体外抗肿瘤活性研究
采用MTT[3-(4,5)-双甲基-2-噻唑-(2,5)-苯基溴化四氮唑蓝]法来测定二氢吡唑磺胺衍生物对人乳腺癌细胞(MCF-7)、肺癌细胞(A549)的半数抑制浓度(IC50)。
(1)培养液(每升)的配制:①悬浮细胞:RPMI-1640培养粉一袋(10.4g),新生牛血清100mL,青霉素溶液(20万U/mL)0.5mL,链霉素溶液(20万U/mL)0.5mL,加三蒸水溶解后,用5.6%的NaHCO3溶液调PH值至7.2-7.4,最后定容至1000mL。过滤灭菌。②贴壁细胞:同上,再加入NaHCO32.00g,HEPES2.38g。
(2)D-Hanks缓冲液(每升)的配制:NaCl8.00g,KCl0.40g,Na2HPO4·12H2O0.06g,KH2PO40.06g,NaHCO30.35g。高压灭菌。
(3)胰蛋白酶液的配制:利用D-Hanks缓冲液配成浓度为0.5%胰蛋白酶液。过滤除菌。
(4)实验药液的配制:将测试样品用少量的三蒸水溶解配成储备液,一般按实验最高浓度的10倍配制储备液。根据化合物溶解性不同,可用三蒸水直接溶解,或用少量DMSO助溶,再加三蒸水溶解。DMSO在培养液中的浓度不宜过大,加药后的每孔细胞悬液中DMSO的终浓度一般不超过0.05%-0.1%。储备液保存于-20℃冰箱中备用。
(5)人乳腺癌细胞(MCF-7)、肺癌细胞(A549)的培养:为悬浮生长细胞,常规培养于RPMI-1640培养液内(含10%小牛血清、100U/mL链霉素),置于37℃、5%CO2培养箱中培养,每隔3-4天传代一次。传代时将原瓶中培养液转移至离心管中,1000rpm离心5min,弃去原培养液,加入等量新鲜培养液,吹打均匀,移取适量至新鲜培养瓶中,再补充新鲜培养液至原体积(培养液体积约为培养瓶容量的1/10)。
(6)细胞孵育:取对数生长期的肿瘤细胞,调细胞悬液浓度为1-1.5×105个mL-1。在96孔培养板中每孔加细胞悬液100μL,置37℃,5%CO2培养箱中培养24h。培养24h后,分别按设计加入药液。
(8)加药:将测试药液按照最终浓度的浓度梯度分别加入到各个孔中,每个浓度设6个平行孔。实验分为药物试验组(分别加入不同浓度的测试药)、对照组(只加培养液和细胞,不加测试药)和空白组(只加培养液,不加细胞和测试药)。将加药后的96孔板置于37℃,5%CO2培养箱中培养48h。阳性对照药物的活性按照测试样品的方法测定。
(9)存活细胞的测定:在培养了48h后的96孔板中,每孔加MTT40μL(用D-Hanks缓冲液配成4mg/mL)。在37℃放置4h后,移去上清液。每孔加150μL DMSO,振荡5min,使formazan结晶溶解。最后,利用自动酶标仪在570nm波长处检测各孔的光密度(OD值)。
半数抑制浓度(IC50)定义为当50%的肿瘤细胞存活时的药物浓度。根据测定的光密度(OD值),制作细胞生长抑制率的标准曲线,在标准曲线上求得其对应的药物浓度。
测得的IC50见表1所示。
表1 本发明所列水杨醛的二氢吡唑磺胺衍生物对肿瘤细胞的抑制IC50值(μg/mL)
Claims (2)
2.根据权利要求所述水杨醛的二氢吡唑磺胺衍生物在制备抗肿瘤药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310541156.6A CN103664786A (zh) | 2013-11-04 | 2013-11-04 | 一类水杨醛的二氢吡唑磺胺衍生物的合成及在抗癌药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310541156.6A CN103664786A (zh) | 2013-11-04 | 2013-11-04 | 一类水杨醛的二氢吡唑磺胺衍生物的合成及在抗癌药物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103664786A true CN103664786A (zh) | 2014-03-26 |
Family
ID=50303666
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310541156.6A Pending CN103664786A (zh) | 2013-11-04 | 2013-11-04 | 一类水杨醛的二氢吡唑磺胺衍生物的合成及在抗癌药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103664786A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104211642A (zh) * | 2014-08-29 | 2014-12-17 | 南京大学 | 一类含四氢化萘或色满骨架的二氢吡唑磺胺衍生物的合成及在抗癌药物中的应用 |
CN104230904A (zh) * | 2014-08-29 | 2014-12-24 | 南京大学 | 一类含萘环骨架的二氢吡唑磺胺衍生物的合成及在抗癌药物中的应用 |
CN104447712A (zh) * | 2014-10-21 | 2015-03-25 | 南京大学 | 一类含1,4-苯并二噁烷骨架的2-苯乙烯基-5-硝基咪唑衍生物的合成及生物活性评价 |
CN105037268A (zh) * | 2015-07-09 | 2015-11-11 | 南京大学 | 一类磺胺苯吡唑酰腙衍生物的合成及在抗癌药物中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102702062A (zh) * | 2012-07-04 | 2012-10-03 | 南京大学 | 一类3,5-二苯基-2h-吡唑衍生物的合成、制备方法及抗癌作用 |
-
2013
- 2013-11-04 CN CN201310541156.6A patent/CN103664786A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102702062A (zh) * | 2012-07-04 | 2012-10-03 | 南京大学 | 一类3,5-二苯基-2h-吡唑衍生物的合成、制备方法及抗癌作用 |
Non-Patent Citations (3)
Title |
---|
M.S. ALAM ET AL.: "Synthesis and biological evaluation of some new 2-pyrazolines bearing benzenesulfonamide moiety as potential anti-inflammatory and anti-cancer agents", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》, vol. 46, no. 12, 16 August 2011 (2011-08-16), XP 028108405, DOI: doi:10.1016/j.ejmech.2011.08.015 * |
RAFIA BASHIR ET AL.: "Synthesis of some new 1,3,5-trisubstituted pyrazolines bearing benzene sulfonamide as anticancer and anti-inflammatory agents", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》, vol. 21, no. 14, 26 May 2011 (2011-05-26), pages 4301 - 4305, XP 028234403, DOI: doi:10.1016/j.bmcl.2011.05.061 * |
杨洋等: "手性二氢吡唑类化合物的合成及生物活性研究进展", 《中国化学会第三届全国分子手性学术研讨会论文集》, 30 July 2010 (2010-07-30), pages 7 - 13 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104211642A (zh) * | 2014-08-29 | 2014-12-17 | 南京大学 | 一类含四氢化萘或色满骨架的二氢吡唑磺胺衍生物的合成及在抗癌药物中的应用 |
CN104230904A (zh) * | 2014-08-29 | 2014-12-24 | 南京大学 | 一类含萘环骨架的二氢吡唑磺胺衍生物的合成及在抗癌药物中的应用 |
CN104211642B (zh) * | 2014-08-29 | 2017-10-20 | 南京大学 | 一类含四氢化萘或色满骨架的二氢吡唑磺胺衍生物的合成及在抗癌药物中的应用 |
CN104447712A (zh) * | 2014-10-21 | 2015-03-25 | 南京大学 | 一类含1,4-苯并二噁烷骨架的2-苯乙烯基-5-硝基咪唑衍生物的合成及生物活性评价 |
CN105037268A (zh) * | 2015-07-09 | 2015-11-11 | 南京大学 | 一类磺胺苯吡唑酰腙衍生物的合成及在抗癌药物中的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103664785A (zh) | 一类新颖的二氢吡唑磺胺衍生物的合成及在抗癌药物中的应用 | |
CN103664786A (zh) | 一类水杨醛的二氢吡唑磺胺衍生物的合成及在抗癌药物中的应用 | |
CN104230905A (zh) | 一类含苯并二噁烷骨架的二氢吡唑磺胺衍生物的合成及在抗癌药物中的应用 | |
CN106496123B (zh) | 一种二氢吡唑类衍生物及其制备方法和应用 | |
CN104230904A (zh) | 一类含萘环骨架的二氢吡唑磺胺衍生物的合成及在抗癌药物中的应用 | |
CN102675205B (zh) | 一种吡唑肟醚类化合物及其制备与在抗癌治疗中的应用 | |
CN104945388A (zh) | 4-(3-(3-(4-氯香豆素)-酰腙)-5-苯基-吡唑)苯磺酰胺类衍生物的制备方法及在抗癌药物中的应用 | |
CN108033913A (zh) | 一种二氢吡唑啉衍生物及其制备方法和应用 | |
CN103664926A (zh) | 一类二氢吡唑噻唑衍生物的合成及在抗癌药物中的应用 | |
CN102532082A (zh) | 2,2-二甲基苯并吡喃类化合物及其制备方法和应用 | |
CN104771392A (zh) | 一类组蛋白去乙酰化酶抑制剂及应用 | |
CN103588758A (zh) | 一类含1,4-苯并二噁烷骨架的硝基咪唑衍生物的合成、制备及其在抗癌药物中的应用 | |
CN104829534A (zh) | 一类含萘环骨架的二氢吡唑吗啉衍生物的制备方法及在抗癌药物中的应用 | |
CN104119319B (zh) | 含1,2,3-三氮唑和脲结构单元的嘧啶衍生物及其制备方法和用途 | |
CN107973807A (zh) | 一种三唑并苯并噻唑衍生物及其制备方法和应用 | |
CN102093191A (zh) | 白藜芦醇查耳酮衍生物及其制备方法 | |
CN107827828B (zh) | 含苯酰肼骨架的喹喔啉衍生物及其制备方法和在制备抗肿瘤药物中的应用 | |
CN104961683A (zh) | 一类含萘环骨架的二氢吡唑哌嗪衍生物的制备方法及在抗癌药物中的应用 | |
CN104447705A (zh) | 一类含1-吲哚乙酸-5-硝基咪唑衍生物的合成及其生物活性评价 | |
CN110078717B (zh) | 一种具有抗肿瘤活性的双苯并呋喃—苯并咪唑盐类化合物及其制备方法 | |
CN105037268A (zh) | 一类磺胺苯吡唑酰腙衍生物的合成及在抗癌药物中的应用 | |
CN104211642A (zh) | 一类含四氢化萘或色满骨架的二氢吡唑磺胺衍生物的合成及在抗癌药物中的应用 | |
CN103059001B (zh) | 一种含三氮唑的喹唑啉酮席夫碱及其制备方法 | |
CN103467320B (zh) | 2,5-双取代环戊酮类衍生物及其应用 | |
CN103709146B (zh) | 一类含苯并咪唑结构的喹啉-4-胺衍生物、其制法及医药用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140326 |